Drugs / V110
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05158140 | Jan 2022 → Feb 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00127153 | Mar → May 2005 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00127153 ↗ |
| Modality | Vaccine | “V110, pneumococcal vaccine polyvalent” NCT00127153 ↗ |
| Route | Intramuscular | “Single intramuscular (IM) dose of 0.5 mL V110” NCT05158140 ↗ |